<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="40221">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01910623</url>
  </required_header>
  <id_info>
    <org_study_id>QOL-APL0512</org_study_id>
    <nct_id>NCT01910623</nct_id>
  </id_info>
  <brief_title>Long-Term Quality of Life in Patients With Acute Promyelocytic Leukemia</brief_title>
  <acronym>QOL-APL0512</acronym>
  <official_title>Long-Term Quality of Life in Patients With Acute Promyelocytic Leukemia: a Follow-up Observational Study of Patients Enrolled in the GIMEMA AIDA 0493 and AIDA 200</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano Malattie EMatologiche dell'Adulto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Italiano Malattie EMatologiche dell'Adulto</source>
  <oversight_info>
    <authority>Italy: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will focus on acute promyelocytic leukemia patients who have been diagnosed more
      than 5 years ago and their present quality of life.

      The possible late effects of cancer treatment can include several issues and, thus, there
      has been an increasing interest worldwide in studying the long-term impact of these in
      patients' life.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will focus on long-term survivors as defined by the America Cancer Society, that
      is surviving the initial diagnosis for more than 5 years. Previous research has investigated
      long-term Health Related Quality of Life (HRQOL) in patients with acute myeloid leukemia,
      however, this will be the first research conducted to investigate long-term HRQOL outcomes
      in patients with acute promyelocytic leukemia (APL).

      The potential late effects of cancer treatment can include second malignancies or other
      chronic conditions affecting physical and emotional well-being. Therefore, there has been an
      increasing interest worldwide in evaluating the longer-term impact of cancer and its
      treatment. Currently large cohort of patients enjoys disease-free survival of 5 years or
      longer. However, a disease-free status is not synonymous with a life free of physical and
      psychological health related to the cancer and/or its treatment. Research shows that cancer
      related health concerns persist long after initial treatment and this has been shown in
      several cancer populations including prostate, testicular, breast cancer and lymphoma
      patients. Long-term cancer survivors can experience treatment-induced morbidity (e.g.
      cardiovascular damage due to chemotherapy or radiotherapy; infertility and second tumors),
      chronic disease and treatment-related symptoms, functional impairment, psychosocial
      problems, and practical problems.

      Since the introduction of the vitamin A derivative all-trans retinoic acid (ATRA) as
      front-line therapy for APL, the outcome of this acute leukemia subtype has changed from the
      state of a most frequently fatal leukemia to the condition of a highly curable disease. The
      Italian cooperative group GIMEMA designed in 1993 the AIDA (Atra plus IDArubicin) trial for
      newly diagnosed APL. Results on over 800 patients showed a complete remission (CR) rate &gt;
      90% and an overall survival of 76% and confirmed that the concomitant administration of ATRA
      and chemotherapy is more effective than the sequential administration. Following the
      identification of distinct prognostic categories among APL patients, the GIMEMA group
      designed a new trial (AIDA2000) in which the intensity of post-remission treatment was
      adapted to the relapse risk and 498 patients were enrolled since January 2000. The results
      recently published showed a CR rate &gt;90% with molecular remission rate after third
      consolidation of 98%. The new schedule allowed a Disease Free Survival (DFS) of 86% and
      showed that a risk-adapted strategy including ATRA for consolidation provides an outcome
      improvement in newly diagnosed patients. As reported by an international panel of experts,
      simultaneous ATRA and anthracycline chemotherapy schedules such as those used in the AIDA
      protocols represent the state of the art therapy for newly diagnosed APL.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Cross-Sectional</study_design>
  <primary_outcome>
    <measure>Clinical significance on each of the SF-36 questionnaire scales.</measure>
    <time_frame>One month from study entry.</time_frame>
    <safety_issue>No</safety_issue>
    <description>This will be performed by using HRQOL scores available for the Italian population. This will help identify which specific areas are mostly impaired and to what extent these patients recover in terms of HRQOL over the long run. This kind of comparison, which is only possible when HRQOL cultural-based norms are available, is largely used when investigating long-term HRQOL in cancer survivors and it is widely recognized as one of the most valuable approach in this kind of research setting.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Association  of EORTC-QLQC30 scales with social-demographic and clinical treatment related variables.</measure>
    <time_frame>One month from study entry.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association  of  MDASI scales (i.e., symptom severity and symptom interference) with different treatment strategies tested in the two GIMEMA trials.</measure>
    <time_frame>One month from study entry.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association  of  EORTC-QLQC30 scales with different treatment strategies tested in the two GIMEMA trials.</measure>
    <time_frame>One month from study entry.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of rate of secondary malignancies with different treatment strategies tested in the two GIMEMA trials.</measure>
    <time_frame>One month from study entry</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Possible differences in  EORTC-QLQC30, MDASI and SF-36  scales between  patients  who were  less than eighteen  years old at the time of diagnosis and patients who were at least eighteen years old at the time of diagnosis.</measure>
    <time_frame>One month from study entry</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <condition>Acute Promyelocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Patients being studied</arm_group_label>
    <description>APL patients previously enrolled in GIMEMA AIDA 0493 and AIDA 2000 studies.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Health Related Quality of Life (HRQOL) measures</intervention_name>
    <arm_group_label>Patients being studied</arm_group_label>
    <other_name>SF-36 health survey.</other_name>
    <other_name>EORTC QOL-C30 questionnaire.</other_name>
    <other_name>FACIT-Fatigue questionnaire.</other_name>
    <other_name>Self-administered Comorbidity Questionnaire (SCQ).</other_name>
    <other_name>Multidimensional Scale of Perceived Social Support (MSPSS).</other_name>
    <other_name>MD Anderson Symptom Inventory (MDASI).</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Acute promyelocytic patients previously enrolled in the studies GIMEMA AIDA0493 and
        AIDA2000
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  APL patients previously enrolled in the studies GIMEMA AIDA0493 and AIDA2000
             surviving the initial diagnosis for more than 5 years and are in CR.

          -  Written informed consent provided.

          -  Adult patients at the time of registration onto this study.

        Exclusion Criteria:

          -  Concomitant major psychiatric disorders or cognitive dysfunctions that would
             interfere with a self-reported evaluation.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabio Efficace, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>GIMEMA Foundation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fabio Efficace, PhD</last_name>
    <email>f.efficace@gimema.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>S.O.C. di Ematologia - Azienda Ospedaliera - SS. Antonio e Biagio e Cesare Arrigo</name>
      <address>
        <city>Alessandria</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorella De Paoli, Dr.</last_name>
      <email>ldepaoli@ospedale.al.it</email>
    </contact>
    <investigator>
      <last_name>Lorella De Paoli, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stefania Tamiazzo, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera - Nuovo Ospedale &quot;Torrette&quot;</name>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pietro Leoni, Dr.</last_name>
      <email>pleoni@univpm.it</email>
    </contact>
    <investigator>
      <last_name>Pietro Leoni, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anna Rita Scortechini, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Az.Ospedaliera S.G.Moscati</name>
      <address>
        <city>Avellino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicola Cantore, Dr.</last_name>
      <email>n.cantore@virgilio.it</email>
    </contact>
    <investigator>
      <last_name>Nicola Cantore, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UO Ematologia con trapianto-Università degli Studi di Bari Aldo Moro</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giorgina Specchia, Pr.</last_name>
      <email>g.specchia@ematba.uniba.it</email>
    </contact>
    <investigator>
      <last_name>Giorgina Specchia, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia - Ospedali Riuniti</name>
      <address>
        <city>Bergamo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandro Rambaldi, Pr.</last_name>
      <email>arambaldi@ospedaliriuniti.bergamo.it</email>
    </contact>
    <investigator>
      <last_name>Alessandro Rambaldi, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Luisa Ferrari, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto di Ematologia &quot;Lorenzo e A. Seragnoli&quot; - Università degli Studi di Bologna - Policlinico S. Orsola - Malpighi</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Martinelli, Pr.</last_name>
      <email>martg@tin.it</email>
    </contact>
    <investigator>
      <last_name>Michele Martinelli, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Silvia Piccari, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria di Bolzano - Ospedale Centrale - Ematologia e Centro TMO</name>
      <address>
        <city>Bolzano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincenzo Cassiba, Dr.</last_name>
      <email>vincenzo.cassibba@asbz.it</email>
    </contact>
    <investigator>
      <last_name>Vincenzo Cassiba, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spedali Civili - Brescia - Azienda Ospedaliera - U.O. Ematologia</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Rossi, Dr.</last_name>
      <email>rossig@med.unibs.it</email>
    </contact>
    <investigator>
      <last_name>Giuseppe Rossi, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASL N.8 - Ospedale &quot;A. Businco&quot; - Struttura Complessa di Ematologia e CTMO</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emanuele Angelucci, Pr.</last_name>
      <email>emnang@tin.it</email>
    </contact>
    <investigator>
      <last_name>Emanuele Angelucci, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claudio Romani, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università di Catania - Cattedra di Ematologia - Ospedale &quot;Ferrarotto&quot;</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Di Raimondo, Pr.</last_name>
      <email>diraimon@unict.it</email>
    </contact>
    <investigator>
      <last_name>Francesco Di Raimondo, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dorina Cultrera, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Pugliese Ciaccio - Presidio Ospedaliero A.Pugliese - Unità Operativa di Ematologia</name>
      <address>
        <city>Catanzaro</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefano Molica, Dr.</last_name>
      <email>smolica@libero.it</email>
    </contact>
    <investigator>
      <last_name>Stefano Molica, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico di Careggi</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alberto Bosi, Dr.</last_name>
      <email>alberto.bosi@unifi.it</email>
    </contact>
    <investigator>
      <last_name>Alberto Bosi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS_AOU San Martino-IST-Ematologia 1-Monoblocco 11°piano- lato ponente</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angelo Michele Carella, Dr.</last_name>
      <email>angelomichele.carella@hsanmartino.it</email>
    </contact>
    <investigator>
      <last_name>Angelo Michele Carella, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giammatteo Pica, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Ematologica - DiMI - Università degli Studi di Genova</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco Gobbi, Pr.</last_name>
      <email>gobbi@unige.it</email>
    </contact>
    <investigator>
      <last_name>Marco Gobbi, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia Ospedale &quot;Santa Maria Goretti&quot;</name>
      <address>
        <city>Latina</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angelo De Blasio, Dr.</last_name>
      <email>emato@online.latina.it</email>
    </contact>
    <investigator>
      <last_name>Angelo De Blasio, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Niguarda &quot; Ca Granda&quot;</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valentina Mancini, Dr.</last_name>
      <email>valentina.mancini@ospedaleniguarda.it</email>
    </contact>
    <investigator>
      <last_name>Valentina Mancini, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eleonora Piraino, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Oncologico Modenese - Dipartimento di Oncoematologia</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Morselli, Dr.</last_name>
      <email>morselli.monica@policlinico.mo.it</email>
    </contact>
    <investigator>
      <last_name>Monica Morselli, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giulia Debbia, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>N. Osp. divisione di Ematologia &quot;S.Gerardo dei Tintori!&quot;</name>
      <address>
        <city>Monza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enrico Maria Pogliani, Dr.</last_name>
      <email>enrico.pogliani@unimib.it</email>
    </contact>
    <investigator>
      <last_name>Enrico Maria Pogliani, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Monica Fumagalli, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria - Università degli Studi di Napoli &quot;Federico II&quot; - Facoltà di Medicina e Chirurgia</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabrizio Pane, Dr.</last_name>
      <email>fabrizio.pane@unina.it</email>
    </contact>
    <investigator>
      <last_name>Fabrizio Pane, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Rilievo Nazionale &quot;A. Cardarelli&quot;</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felicetto Ferrara, Pr.</last_name>
      <email>felicettoferrara@katamail.com</email>
    </contact>
    <investigator>
      <last_name>Felicetto Ferrara, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Servizio Sanitario Nazionale - Azienda Ospedaliera di Rilievo Nazionale &quot;A. Cardarelli&quot; - Struttura Complessa di Ematologia - Div. TERE- 4° piano - Padiglione Palermo</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vincenzo Mettivier, Pr.</last_name>
      <email>ematologia_cardarel@libero.it</email>
    </contact>
    <investigator>
      <last_name>Vincenzo Mettivier, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sez. di Ematologia Clinica Ospedale San Francesco</name>
      <address>
        <city>Nuoro</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giancarlo Latte, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Giancarlo Latte, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia con trapianto di midollo - A.U. Policlinico &quot;Paolo Giaccone&quot;</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincenzo Abbadessa, Pr.</last_name>
    </contact>
    <investigator>
      <last_name>Vincenzo Abbadessa, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Enza Mitra, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti &quot;Villa Sofia-Cervello&quot;</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Fabbiano, Pr.</last_name>
      <email>fabbianofrancesco@tiscali.it</email>
    </contact>
    <investigator>
      <last_name>Francesco Fabbiano, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cattedra di Ematologia CTMO Università degli Studi di Parma</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cecilia Caramatti, Dr.</last_name>
      <email>cecilia.caramatti@unipr.it</email>
    </contact>
    <investigator>
      <last_name>Cecilia Caramatti, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>S.C. Ematologia - Fondazione IRCCS Policlinico S. Matteo</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mario Cazzola, Dr.</last_name>
      <email>mario.cazzola@unipv.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sezione di Ematologia ed Immunologia Clinica - Ospedale S.Maria della Misericordia</name>
      <address>
        <city>Perugia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brunangelo Falini, Dr.</last_name>
      <email>faliniem@unipg.it</email>
    </contact>
    <investigator>
      <last_name>Brunangelo Falini, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Paola Martelli, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O. Ematologia Clinica - Azienda USL di Pescara</name>
      <address>
        <city>Pescara</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Fioritoni, Pr.</last_name>
      <email>gfioritoni@tin.it</email>
    </contact>
    <investigator>
      <last_name>Giuseppe Fioritoni, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anna Recchia, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Calabria Dipartimento Emato-Oncologia A.O.&quot;Bianchi-Melacrino-Morelli&quot;</name>
      <address>
        <city>Reggio Calabria</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Nobile, Pr.</last_name>
      <email>nobilefranc@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Francesco Nobile, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caterina Alati, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unità Operativa Complessa di Ematologia - Arcispedale S. Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francesco Merli, Dr.</last_name>
      <email>francesco.merli@asmn.re.it</email>
    </contact>
    <investigator>
      <last_name>Francesco Merli, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O.C. Ematologia - Ospedale S.Eugenio</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo De Fabritiis, Pr.</last_name>
      <email>paolo.de.fabritiis@uniroma2.it</email>
    </contact>
    <investigator>
      <last_name>Paolo De Fabritiis, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UOC Pronto Soccorso e Accettazione Ematologica - Dipartimento Biotecnologie Cellulari ed Ematologia - Università degli Studi di Roma &quot;Sapienza&quot;</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuliana Alimena, Pr.</last_name>
      <email>alimena@bce.uniroma1.it</email>
    </contact>
    <investigator>
      <last_name>Giuliana Alimena, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Massimo Breccia, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università Cattolica del Sacro Cuore - Policlinico A. Gemelli</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Leone, Pr.</last_name>
      <email>gleone@rm.unicatt.it</email>
    </contact>
    <investigator>
      <last_name>Giuseppe Leone, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Simona Sica, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto di Ematologia - IRCCS Ospedale Casa Sollievo della Sofferenza</name>
      <address>
        <city>S. G. Rotondo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicola Cascavilla, Pr.</last_name>
      <email>n.cascavilla@operapadrepio.it</email>
    </contact>
    <investigator>
      <last_name>Nicola Cascavilla, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SCDO Ematologia 2 AOU S.Giovanni Battista</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Umberto Vitolo, Dr.</last_name>
      <email>uvitolo@molinette.piemonte.it</email>
    </contact>
    <investigator>
      <last_name>Umberto Vitolo, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stefano D'ardia, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Ematologica - Policlinico Universitario</name>
      <address>
        <city>Udine</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renato Fanin, Pr.</last_name>
      <email>renato.fanin@uniud.it</email>
    </contact>
    <investigator>
      <last_name>Renato Fanin, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università degli Studi di Verona - A. O. - Istituti Ospitalieri di Verona- Div. di Ematologia - Policlinico G.B. Rossi</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Pizzolo, Pr.</last_name>
      <email>giovanni.pizzolo@univr.it</email>
    </contact>
    <investigator>
      <last_name>Giovanni Pizzolo, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ULSS N.6 Osp. S. Bortolo</name>
      <address>
        <city>Vicenza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Rodeghiero, Pr.</last_name>
      <email>rodeghiero@hemato.ven.it</email>
    </contact>
    <investigator>
      <last_name>Francesco Rodeghiero, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eros Di Bona, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.gimema.org/wp_qol.php</url>
    <description>GIMEMA Quality of Life Working Party</description>
  </link>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 30, 2014</lastchanged_date>
  <firstreceived_date>March 28, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Quality of life</keyword>
  <keyword>Health related quality of life outcomes</keyword>
  <keyword>Long-term</keyword>
  <keyword>Aida 0493</keyword>
  <keyword>AIDA 2000</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Promyelocytic, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
